Robby Booth serves as Glytec’s Chief Strategy and Research Officer, facilitating the company’s innovation programs, patent inventions and FDA clearances as well as multiple partnerships with vendors of complementary technologies. He has 20 years of experience in developing and commercializing disruptive solutions. Robby is one of Glytec’s founders and has been instrumental in advancing the company’s solutions for diabetes therapy management, including new models, algorithms and software-as-a-medical-device products for personalized digital therapeutics. He is an inventor of nearly one hundred pending and granted U.S. and international patents and co-author of 30+ scientific abstracts. Robby holds a bachelor of science in business studies and international management from Southern New Hampshire University, and a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society. He is a Certified Professional in Healthcare Quality (CPHQ) , Certified Quality Auditor (CQA), and Six Sigma Master Black Belt.